SLC5A2 and type 2 diabetes mellitus: At the same time, the latest meta-analysis showed that chronic treatment (with a minimum duration of 2 weeks to 6 months) using an SGLT2 inhibitor was associated with a significantly reduced risk of CI-AKI in T2DM patients undergoing coronary procedures, compared with the control group (RR = 0.48,95%CI:0.39–0.59, p < 0.001) (36).